Simcere Pharmaceutical Group Overview
- Year Founded
-
1995
- Status
-
Public
- Employees
-
6,584
- Stock Symbol
-
02096
- Investments
-
17
- Share Price
-
$1.10
- (As of Friday Closing)
Simcere Pharmaceutical Group General Information
Description
Simcere Pharmaceutical Group Ltd is engaged in the R&D, production, and commercialization of pharmaceuticals focused on generic pharmaceuticals. It has a diversified product portfolio focused on therapeutic areas, including, oncology (including cell therapy), nervous system diseases, autoimmune diseases, and antiinfection. The company's products include Endostar, Enweida, Iremod, Sanbexin and Others.
Contact Information
Website
www.simcere.comCorporate Office
- Number 699-18, Xuanwu Avenue
- Nanjing, Jiangsu 210042
- China
Corporate Office
- Number 699-18, Xuanwu Avenue
- Nanjing, Jiangsu 210042
- China
Simcere Pharmaceutical Group Stock Performance
As of 25-Apr-2025, Simcere Pharmaceutical Group’s stock price is $1.10. Its current market cap is $2.72B with 2.47B shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.10 | $1.13 | $0.65 - $1.17 | $2.72B | 2.47B | 6.53M | $0.04 |
Simcere Pharmaceutical Group Financials Summary
As of 31-Dec-2024, Simcere Pharmaceutical Group has a trailing 12-month revenue of $925M.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 1,990,304 | 1,990,304 | 2,074,991 | 3,769,344 |
| Revenue | 924,709 | 924,709 | 933,981 | 939,052 |
| EBITDA | 165,544 | 165,544 | 145,478 | 169,936 |
| Net Income | 102,177 | 102,177 | 101,028 | 138,223 |
| Total Assets | 1,576,681 | 1,576,681 | 1,531,144 | 1,563,775 |
| Total Debt | 165,665 | 165,665 | 201,623 | 218,391 |
Simcere Pharmaceutical Group Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Simcere Pharmaceutical Group Comparisons
Industry
Financing
Details
Simcere Pharmaceutical Group Competitors (1)
One of Simcere Pharmaceutical Group’s competitors is Emcure Pharmaceuticals, a Formerly PE-Backed company based in Pune, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Emcure Pharmaceuticals | Formerly PE-Backed | Pune, India |
Simcere Pharmaceutical Group Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Simcere Pharmaceutical Group Patents
Simcere Pharmaceutical Group Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4365183-A1 | Steroid compound, and pharmaceutical composition thereof and use thereof | Pending | 24-Jun-2021 | ||
| US-20240307415-A1 | Steroid compound, and pharmaceutical composition thereof and use thereof | Pending | 24-Jun-2021 | ||
| JP-2024523545-A | Steroid compounds, pharmaceutical compositions thereof and their applications | Pending | 24-Jun-2021 | ||
| US-20240084003-A1 | Anti-human cd22 monoclonal antibodies and use thereof | Pending | 18-Jan-2021 | ||
| US-20240076403-A1 | Her2 antibody and application thereof | Pending | 18-Dec-2020 | C07K16/32 |
Simcere Pharmaceutical Group Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Simcere Pharmaceutical Group Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Simcere Pharmaceutical Group Investments (17)
Simcere Pharmaceutical Group’s most recent deal was a Later Stage VC with AnDiConBio for . The deal was made on 30-Apr-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| AnDiConBio | 30-Apr-2024 | Later Stage VC | Drug Discovery | ||
| Tobishi Pharmaceutical | 07-Apr-2024 | Corporate | Therapeutic Devices | ||
| AnDiConBio | 08-Nov-2023 | Later Stage VC | Drug Discovery | ||
| NeuroDawn Pharmaceutical | 06-Feb-2023 | Early Stage VC | Drug Discovery | ||
| Carmine Therapeutics | 29-Nov-2022 | Early Stage VC | Biotechnology |
Simcere Pharmaceutical Group ESG
Risk Overview
Risk Rating
Updated October, 15, 2024
32.01 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,109
Rank
Percentile
Pharmaceuticals
Industry
of 861
Rank
Percentile
Pharmaceuticals
Subindustry
of 430
Rank
Percentile
Simcere Pharmaceutical Group Exits (3)
Simcere Pharmaceutical Group’s most recent exit was on 23-Dec-2019 from 3D Medicines. The exit was categorized as with 6 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 3D Medicines | 23-Dec-2019 | Completed |
|
||
| I-Mab Biopharma | 30-Jun-2016 | Completed |
|
||
| Shanghai Celgen Biopharma | 01-Aug-2009 | Corporate | Completed |
Simcere Pharmaceutical Group Affiliates
Subsidiaries (3)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Simcere Zaiming | Haikou, China | 2020 | |
| Simcere | Nanjing, China | 2017 | |
| Jilin Boda pharmaceutical | Liaoyuan, China | 1995 |
Simcere Pharmaceutical Group FAQs
-
When was Simcere Pharmaceutical Group founded?
Simcere Pharmaceutical Group was founded in 1995.
-
Where is Simcere Pharmaceutical Group headquartered?
Simcere Pharmaceutical Group is headquartered in Nanjing, China.
-
What is the size of Simcere Pharmaceutical Group?
Simcere Pharmaceutical Group has 6,584 total employees.
-
What industry is Simcere Pharmaceutical Group in?
Simcere Pharmaceutical Group’s primary industry is Pharmaceuticals.
-
Is Simcere Pharmaceutical Group a private or public company?
Simcere Pharmaceutical Group is a Public company.
-
What is Simcere Pharmaceutical Group’s stock symbol?
The ticker symbol for Simcere Pharmaceutical Group is 02096.
-
What is the current stock price of Simcere Pharmaceutical Group?
As of 25-Apr-2025 the stock price of Simcere Pharmaceutical Group is $1.10.
-
What is the current market cap of Simcere Pharmaceutical Group?
The current market capitalization of Simcere Pharmaceutical Group is $2.72B.
-
What is Simcere Pharmaceutical Group’s current revenue?
The trailing twelve month revenue for Simcere Pharmaceutical Group is $925M.
-
Who are Simcere Pharmaceutical Group’s competitors?
Emcure Pharmaceuticals is a competitor of Simcere Pharmaceutical Group.
-
What is Simcere Pharmaceutical Group’s annual earnings per share (EPS)?
Simcere Pharmaceutical Group’s EPS for 12 months was $0.04.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
